Whitepaper: Early Product Characterization Mitigates Risks in Biologics Development

Product characterization has become much more complicated with the increased focus on biologics. Despite this, it is an essential part of the drug development process that can no longer be standardized. Learn more about product characterization and how to implement effective strategies In a new whitepaper by BioReliance.

According to BioReliance, “The complexities of biological manufacturing, the large size of the molecules, and the product heterogeneity Introduced by cellular expression systems present significant challenges to measuring the quality of a biologic drug. During the early phase of drug development, much about the drug’s quality ”

To download your free copy, click here.

(Source: BioReliance, August 30^th, 2022)